Variations in MHC Class II Antigen Processing and Presentation in Health and Disease

Annual Review of Immunology

Volumn 34, Issue , 2016, Pages 265-297

  Unanue, Emil R ^a   Turk, Vito ^b   Neefjes, Jacques ^c,d  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JO EF STEFAN INSTITUTE   (Slovenia)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antigen presentation; Autoimmunity; Cathepsins; HLA; Inhibitors; MHC class II; Polymorphism; Processing

Indexed keywords

CATHEPSIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEINASE; PROTEINASE INHIBITOR; TOLL LIKE RECEPTOR; ANTIGEN; HLA ANTIGEN CLASS 2; PEPTIDE FRAGMENT;

ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNITY; AUTOPHAGY; DISEASES; GENETIC CODE; HEALTH; HUMAN; IMMUNE RESPONSE; NONHUMAN; PHAGOCYTOSIS; PHAGOSOME; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN METABOLISM; PROTEIN PROCESSING; TISSUE DISTRIBUTION; TISSUE SPECIFICITY; TISSUE STRUCTURE; TRANSCRIPTION REGULATION; ANIMAL; ENDOCYTOSIS; ENDOSOME; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETICS; GLYCOSYLATION; IMMUNOLOGY; IMMUNOPATHOLOGY; METABOLISM; PROTEIN TRANSPORT;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS; AUTOIMMUNITY; ENDOCYTOSIS; ENDOSOMES; GENE EXPRESSION REGULATION; GLYCOSYLATION; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNE SYSTEM DISEASES; PEPTIDE FRAGMENTS; POLYMORPHISM, GENETIC; PROTEIN TRANSPORT; PROTEOLYSIS;

EID: 84969884870     PISSN: 07320582     EISSN: 15453278     Source Type: Book Series    
DOI: 10.1146/annurev-immunol-041015-055420     Document Type: Article

References (207)

1. Neefjes J, Jongsma ML, Paul P, Bakke O. 2011. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat. Rev. Immunol. 11:823-36
2. Kambayashi T, Laufer TM. 2014. Atypical MHC class II-expressing antigen-presenting cells: Can anything replace a dendritic cell? Nat. Rev. Immunol. 14:719-30
3. Kared H, Camous X, Larbi A. 2014. T cells and their cytokines in persistent stimulation of the immune system. Curr. Opin. Immunol. 29:79-85
4. Fernando MM, Stevens CR, Walsh EC, De Jager PL, Goyette P, et al. 2008. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLOS Genet. 4:e1000024
5. Dilthey A, Cox C, Iqbal Z, Nelson MR, McVean G. 2015. Improved genome inference in the MHC using a population reference graph. Nat. Genet. 47:682-88
6. Stern LJ, Brown JH, Jardetzky TS, Gorga JC, Urban RG, et al. 1994. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368:215-21
7. Beck S, Trowsdale J. 2000. The human major histocompatability complex: lessons from the DNA sequence. Annu. Rev. Genom. Hum. Genet. 1:117-37
8. Jardetzky TS, Brown JH, Gorga JC, Stern LJ, Urban RG, et al. 1996. Crystallographic analysis of endogenous peptides associated with HLA-DR1 suggests a common, polyproline II-like conformation for bound peptides. PNAS 93:734-38
9. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. 1994. Pool sequencing of natural HLADR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing, and general rules. Immunogenetics 39:230-42
10. Rossjohn J, Gras S, Miles JJ, Turner SJ, Godfrey DI, McCluskey J. 2015. T cell antigen receptor recognition of antigen-presenting molecules. Annu. Rev. Immunol. 33:169-200
11. Castellino F, Zappacosta F, Coligan JE, Germain RN. 1998. Large protein fragments as substrates for endocytic antigen capture by MHC class II molecules. J. Immunol. 161:4048-57
12. Sercarz EE, Maverakis E. 2003. MHC-guided processing: binding of large antigen fragments. Nat. Rev. Immunol. 3:621-29
13. Zhang P, Leu JI, Murphy ME, George DL, Marmorstein R. 2014. Crystal structure of the stressinducible human heat shock protein 70 substrate-binding domain in complex with peptide substrate. PLOS ONE 9:e103518
14. Hughes AL. 2002. Natural selection and the diversification of vertebrate immune effectors. Immunol. Rev. 190:161-68
15. Trowsdale J, Parham P. 2004. Mini-review: defense strategies and immunity-related genes. Eur. J. Immunol. 34:7-17
16. Siddle HV, Kreiss A, Eldridge MD, Noonan E, Clarke CJ, et al. 2007. Transmission of a fatal clonal tumor by biting occurs due to depleted MHC diversity in a threatened carnivorous marsupial. PNAS 104:16221-26
17. Pos W, Sethi DK, Call MJ, Schulze MS, Anders AK, et al. 2012. Crystal structure of the HLA-DMHLA-DR1 complex defines mechanisms for rapid peptide selection. Cell 151:1557-68
18. Boog CJ, Neefjes JJ, Boes J, Ploegh HL, Melief CJ. 1989. Specific immune responses restored by alteration in carbohydrate chains of surface molecules on antigen-presenting cells. Eur. J. Immunol. 19:537-42
19. Bolscher JG, van Bijl MM, Neefjes JJ, Hall A, Smets LA, Ploegh HL. 1988. Ras (proto)oncogene induces N-linked carbohydrate modification: temporal relationship with induction of invasive potential. EMBO J. 7:3361-68
20. Neefjes JJ, De Bruijn ML, Boog CJ, Nieland JD, Boes J, et al. 1990. N-linked glycan modification on antigen-presenting cells restores an allospecific cytotoxic T cell response. J. Exp. Med. 171:583-88
21. Blum JS,Wearsch PA, Cresswell P. 2013. Pathways of antigen processing. Annu. Rev. Immunol. 31:443-73
22. Roche PA, Marks MS, Cresswell P. 1991. Formation of a nine-subunit complex by HLA class II glycoproteins and the invariant chain. Nature 354:392-94
23. Romagnoli P, Germain RN. 1994. The CLIP region of invariant chain plays a critical role in regulating major histocompatibility complex class II folding, transport, and peptide occupancy. J. Exp. Med. 180:1107-13
24. Roche PA, Cresswell P. 1991. Proteolysis of the class II-associated invariant chain generates a peptide binding site in intracellular HLA-DR molecules. PNAS 88:3150-54
25. Zhong G, Castellino F, Romagnoli P, Germain RN. 1996. Evidence that binding site occupancy is necessary and sufficient for effective major histocompatibility complex (MHC) class II transport through the secretory pathway redefines the primary function of class II-associated invariant chain peptides (CLIP). J. Exp. Med. 184:2061-66
26. Neefjes JJ, Stollorz V, Peters PJ, Geuze HJ, Ploegh HL. 1990. The biosynthetic pathway of MHC class II but not class I molecules intersects the endocytic route. Cell 61:171-83
27. Peters PJ, Neefjes JJ, Oorschot V, Ploegh HL, Geuze HJ. 1991. Segregation ofMHC class II molecules from MHC class I molecules in the Golgi complex for transport to lysosomal compartments. Nature 349:669-76
28. Bakke O, Dobberstein B. 1990. MHC class II-associated invariant chain contains a sorting signal for endosomal compartments. Cell 63:707-16
29. Bikoff EK,Huang LY, Episkopou V, Meerwijk J, Germain RN, Robertson EJ. 1993. Defectivemajor histocompatibility complex class II assembly, transport, peptide acquisition, and CD4+ T cell selection in mice lacking invariant chain expression. J. Exp. Med. 177:1699-712
30. Viville S, Neefjes J, Lotteau V, Dierich A, Lemeur M, et al. 1993. Mice lacking the MHC class II-associated invariant chain. Cell 72:635-48
31. Villadangos JA, Bryant RA,Deussing J, DriessenC,Lennon-DumenilAM, et al. 1999. Proteases involved in MHC class II antigen presentation. Immunol. Rev. 172:109-20
32. Bergmann H, YabasM, Short A, Miosge L, BarthelN, et al. 2013.Bcell survival, surfaceBCRandBAFFR expression, CD74 metabolism, and CD8-dendritic cells require the intramembrane endopeptidase SPPL2A. J. Exp. Med. 210:31-40
33. Beisner DR, Langerak P, Parker AE, Dahlberg C, Otero FJ, et al. 2013. The intramembrane protease Sppl2a is required for B cell and DC development and survival via cleavage of the invariant chain. J. Exp. Med. 210:23-30
34. Neefjes JJ, Ploegh HL. 1992. Inhibition of endosomal proteolytic activity by leupeptin blocks surface expression of MHC class II molecules and their conversion to SDS resistance αβ heterodimers in endosomes. EMBO J. 11:411-16
35. Ghosh P, Amaya M, Mellins E, Wiley DC. 1995. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 378:457-62
36. Anders AK, Call MJ, Schulze MS, Fowler KD, Schubert DA, et al. 2011. HLA-DM captures partially empty HLA-DR molecules for catalyzed removal of peptide. Nat. Immunol. 12:54-61
37. Sherman MA,Weber DA, Jensen PE. 1995. DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide. Immunity 3:197-205
38. Mosyak L, Zaller DM, Wiley DC. 1998. The structure of HLA-DM, the peptide exchange catalyst that loads antigen onto class II MHC molecules during antigen presentation. Immunity 9:377-83
39. Fremont DH, Crawford F, Marrack P, Hendrickson WA, Kappler J. 1998. Crystal structure of mouse H2-M. Immunity 9:385-93
40. Doebele RC, Pashine A, Liu W, Zaller DM, Belmares M, et al. 2003. Point mutations in or near the antigen-binding groove of HLA-DR3 implicate class II-associated invariant chain peptide affinity as a constraint on MHC class II polymorphism. J. Immunol. 170:4683-92
41. Kropshofer H, Vogt AB, Moldenhauer G, Hammer J, Blum JS, Hammerling GJ. 1996. Editing of the HLA-DR-peptide repertoire by HLA-DM. EMBO J. 15:6144-54
42. Denzin LK, Cresswell P. 1995. HLA-DM induces CLIP dissociation fromMHC class II αβdimers and facilitates peptide loading. Cell 82:155-65
43. Cella M, Engering A, PinetV,Pieters J, Lanzavecchia A. 1997. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 388:782-87
44. Pierre P, Turley SJ, Gatti E, Hull M, Meltzer J, et al. 1997. Developmental regulation of MHC class II transport in mouse dendritic cells. Nature 388:787-92
45. Martin WD, Hicks GG, Mendiratta SK, Leva HI, Ruley HE, Van Kaer L. 1996. H2-M mutant mice are defective in the peptide loading of class II molecules, antigen presentation, and T cell repertoire selection. Cell 84:543-50
46. Chapman DC, Williams DB. 2010. ER quality control in the biogenesis of MHC class I molecules. Semin. Cell Dev. Biol. 21:512-19
47. Marks MS, Roche PA, van Donselaar E, Woodruff L, Peters PJ, Bonifacino JS. 1995. A lysosomal targeting signal in the cytoplasmic tail of the βchain directs HLA-DM to MHC class II compartments. J. Cell Biol. 131:351-69
48. De Gassart A, Camosseto V, Thibodeau J, Ceppi M, Catalan N, et al. 2008.MHCclass II stabilization at the surface of human dendritic cells is the result of maturation-dependent MARCH I down-regulation. PNAS 105:3491-96
49. Shin JS, Ebersold M, PypaertM, Delamarre L, Hartley A,Mellman I. 2006. Surface expression ofMHC class II in dendritic cells is controlled by regulated ubiquitination. Nature 444:115-18
50. Boname JM, Lehner PJ. 2011. What has the study of the K3 and K5 viral ubiquitin E3 ligases taught us about ubiquitin-mediated receptor regulation? Viruses 3:118-31
51. Lapaque N, Hutchinson JL, Jones DC, Meresse S, Holden DW, et al. 2009. Salmonella regulates polyubiquitination and surface expression of MHC class II antigens. PNAS 106:14052-57
52. Matsuki Y, Ohmura-Hoshino M, Goto E, Aoki M, Mito-Yoshida M, et al. 2007. Novel regulation of MHC class II function in B cells. EMBO J. 26:846-54
53. Cho KJ, Walseng E, Ishido S, Roche PA. 2015. Ubiquitination by March-I prevents MHC class II recycling and promotes MHC class II turnover in antigen-presenting cells. PNAS 112:10449-54
54. NielG,Wubbolts R, Ten Broeke T, Buschow SI, Ossendorp FA, et al. 2006. Dendritic cells regulate exposure of MHC class II at their plasma membrane by oligoubiquitination. Immunity 25:885-94
55. Amigorena S, Drake JR, Webster P, Mellman I. 1994. Transient accumulation of new class II MHC molecules in a novel endocytic compartment in B lymphocytes. Nature 369:113-20
56. Neefjes J. 1999. CIIV, MIIC and other compartments for MHC class II loading. Eur. J. Immunol. 29:1421-25
57. Allen PM, Unanue ER. 1984. Differential requirements for antigen processing by macrophages for lysozyme-specific T cell hybridomas. J. Immunol. 132:1077-79
58. Pierre P, Denzin LK, Hammond C, Drake JR, Amigorena S, et al. 1996. HLA-DM is localized to conventional and unconventional MHC class II-containing endocytic compartments. Immunity 4:229-39
59. Li M, Rong Y, Chuang YS, Peng D, Emr SD. 2015. Ubiquitin-dependent lysosomal membrane protein sorting and degradation. Mol. Cell 57:467-78
60. Sanderson F, Kleijmeer MJ, Kelly A, Verwoerd D, Tulp A, et al. 1994. Accumulation of HLA-DM, a regulator of antigen presentation, in MHC class II compartments. Science 266:1566-69
61. Hammond C, Denzin LK, Pan M, Griffith JM, Geuze HJ, Cresswell P. 1998. The tetraspan protein CD82 is a resident of MHC class II compartments where it associates with HLA-DR,-DM, and-DO molecules. J. Immunol. 161:3282-91
62. Hoorn T, Paul P, Janssen L, Janssen H, Neefjes J. 2012. Dynamics within tetraspanin pairs affectMHC class II expression. J. Cell Sci. 125:328-39
63. Segura E, Guerin C, Hogg N, Amigorena S, Thery C. 2007. CD8+ dendritic cells use LFA-1 to capture MHC-peptide complexes from exosomes in vivo. J. Immunol. 179:1489-96
64. Zwart W, Griekspoor A, Kuijl C, Marsman M, van Rheenen J, et al. 2005. Spatial separation of HLADM/ HLA-DR interactions within MIIC and phagosome-induced immune escape. Immunity 22:221-33
65. Arunachalam B, Phan UT, Geuze HJ, Cresswell P. 2000. Enzymatic reduction of disulfide bonds in lysosomes: characterization of aγ-interferon-inducible lysosomal thiol reductase (GILT).PNAS97:745-50
66. Fernandez-BorjaM, Verwoerd D, Sanderson F, Aerts H, Trowsdale J, et al. 1996. HLA-DM andMHC class II molecules co-distribute with peptidase-containing lysosomal subcompartments. Int. Immunol. 8:625-40
67. Bosch B, Berger AC, Khandelwal S, Heipertz EL, Scharf B, et al. 2013. Disruption ofmultivesicular body vesicles does not affect major histocompatibility complex (MHC) class II-peptide complex formation and antigen presentation by dendritic cells. J. Biol. Chem. 288:24286-92
68. Moss CX, Villadangos JA, Watts C. 2005. Destructive potential of the aspartyl protease cathepsin D in MHC class II-restricted antigen processing. Eur. J. Immunol. 35:3442-51
69. Shi GP, Villadangos JA, Dranoff G, Small C, Gu L, et al. 1999. Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity 10:197-206
70. Nakagawa TY, Brissette WH, Lira PD, Griffiths RJ, PetrushovaN, et al. 1999. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S nullmice. Immunity 10:207-17
71. Tolosa E, Li W, Yasuda Y, Wienhold W, Denzin LK, et al. 2003. Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis. J. Clin. Investig. 112:517-26
72. Yamamoto K, Kawakubo T, Yasukochi A, Tsukuba T. 2012. Emerging roles of cathepsin E in host defense mechanisms. Biochim. Biophys. Acta 1824:105-12
73. Rossi A, Deveraux Q, Turk B, Sali A. 2004. Comprehensive search for cysteine cathepsins in the human genome. Biol. Chem. 385:363-72
74. Heng TS, Painter MW. 2008. The Immunological Genome Project: networks of gene expression in immune cells. Nat. Immunol. 9:1091-94
75. Delamarre L, Pack M, Chang H, Mellman I, Trombetta ES. 2005. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science 307:1630-34
76. McCurley N, Mellman I. 2010. Monocyte-derived dendritic cells exhibit increased levels of lysosomal proteolysis as compared to other human dendritic cell populations. PLOS ONE 5:e11949
77. Musil D, Zucic D, Turk D, Engh RA, Mayr I, et al. 1991. The refined 2.15A X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity. EMBO J. 10:2321-30
78. Turk D, Janjic V, Stern I, Podobnik M, Lamba D, et al. 2001. Structure of human dipeptidyl peptidase I (cathepsin C): exclusion domain added to an endopeptidase framework creates the machine for activation of granular serine proteases. EMBO J. 20:6570-82
79. Turk D, Guncar G. 2003. Lysosomal cysteine proteases (cathepsins): promising drug targets. Acta Crystallogr. D 59:203-13
80. Nagler DK, Zhang R, TamW, Sulea T, Purisima EO, Menard R. 1999. Human cathepsin X: a cysteine protease with unique carboxypeptidase activity. Biochemistry 38:12648-54
81. Groves MR, Coulombe R, Jenkins J, Cygler M. 1998. Structural basis for specificity of papain-like cysteine protease proregions toward their cognate enzymes. Proteins 32:504-14
82. Jerala R, Zerovnik E, Kidric J,TurkV. 1998. pH-induced conformational transitions of the propeptide of human cathepsin L: a role for amolten globule state in zymogen activation. J. Biol. Chem. 273:11498-504
83. Pierre P, Mellman I. 1998. Developmental regulation of invariant chain proteolysis controlsMHC class II trafficking in mouse dendritic cells. Cell 93:1135-45
84. AbrahamsonM, Alvarez-Fernandez M, Nathanson CM. 2003. Cystatins. Biochem. Soc. Symp. 2003:179-99
85. Turk V, Stoka V, TurkD. 2008. Cystatins: biochemical and structural properties, andmedical relevance. Front. Biosci. 13:5406-20
86. Hall A, Hakansson K, Mason RW, Grubb A, Abrahamson M. 1995. Structural basis for the biological specificity of cystatin C: identification of leucine 9 in the N-terminal binding region as a selectivityconferring residue in the inhibition of mammalian cysteine peptidases. J. Biol. Chem. 270:5115-21
87. El-Sukkari D, Wilson NS,HakanssonK, Steptoe RJ,Grubb A, et al. 2003. The protease inhibitor cystatin C is differentially expressed among dendritic cell populations, but does not control antigen presentation. J. Immunol. 171:5003-11
88. Salvesen G, Parkes C, Abrahamson M, Grubb A, Barrett AJ. 1986. Human low-Mr kininogen contains three copies of a cystatin sequence that are divergent in structure and in inhibitory activity for cysteine proteinases. Biochem. J. 234:429-34
89. Turk B, Stoka V, Turk V, Johansson G, Cazzulo JJ, Bjork I. 1996. High-molecular-weight kininogen binds two molecules of cysteine proteinases with different rate constants. FEBS Lett. 391:109-12
90. Turk V, Stoka V, Vasiljeva O, RenkoM, Sun T, et al. 2012. Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim. Biophys. Acta 1824:68-88
91. Wiener JJ, Sun S, Thurmond RL. 2010. Recent advances in the design of cathepsin S inhibitors. Curr. Top. Med. Chem. 10:717-32
92. Saegusa K, Ishimaru N, Yanagi K, Arakaki R, Ogawa K, et al. 2002. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. J. Clin. Investig. 110:361-69
93. Rupanagudi KV, Kulkarni OP, Lichtnekert J, Darisipudi MN, Mulay SR, et al. 2015. Cathepsin S inhibition suppresses systemic lupus erythematosus and lupus nephritis because cathepsin S is essential for MHC class II-mediated CD4 T cell and B cell priming. Ann. Rheum. Dis. 74:452-63
94. Bevec T, Stoka V, Pungercic G, Dolenc I, Turk V. 1996. Major histocompatibility complex class II-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin L. J. Exp. Med. 183:1331-38
95. Mihelic M, Dobersek A, Guncar G, Turk D. 2008. Inhibitory fragment from the p41 form of invariant chain can regulate activity of cysteine cathepsins in antigen presentation. J. Biol. Chem. 283:14453-60
96. Shachar I, Elliott EA, Chasnoff B, Grewal IS, FlavellRA. 1995. Reconstitution of invariant chain function in transgenic mice in vivo by individual p31 and p41 isoforms. Immunity 3:373-83
97. Schuttelkopf AW,Hamilton G, Watts C, van Aalten DM. 2006. Structural basis of reduction-dependent activation of human cystatin F. J. Biol. Chem. 281:16570-75
98. Alvarez-FernandezM, Liang YH, AbrahamsonM, Su XD. 2005. Crystal structure of human cystatin D, a cysteine peptidase inhibitor with restricted inhibition profile. J. Biol. Chem. 280:18221-28
99. Janowski R, Kozak M, Jankowska E, Grzonka Z, Grubb A, et al. 2001. Human cystatin C, an amyloidogenic protein, dimerizes through three-dimensional domain swapping. Nat. Struct. Biol. 8:316-20
100. Jenko S, Dolenc I, Guncar G, Dobersek A, Podobnik M, Turk D. 2003. Crystal structure of stefin A in complex with cathepsin H: N-terminal residues of inhibitors can adapt to the active sites of endo-and exopeptidases. J. Mol. Biol. 326:875-85
101. Guncar G, Pungercic G, Klemencic I, Turk V, Turk D. 1999. Crystal structure of MHC class II-associated p41 Ii fragment bound to cathepsin L reveals the structural basis for differentiation between cathepsins L and S. EMBO J. 18:793-803
102. Bode W, Engh R, Musil D, Thiele U, Huber R, et al. 1988. The 2.0A X-ray crystal structure of chicken egg white cystatin and its possible mode of interaction with cysteine proteinases. EMBO J. 7:2593-99
103. Stubbs MT, Laber B, Bode W, Huber R, Jerala R, et al. 1990. The refined 2.4A X-ray crystal structure of recombinant human stefin B in complex with the cysteine proteinase papain: a novel type of proteinase inhibitor interaction. EMBO J. 9:1939-47
104. Wubbolts R, Fernandez-Borja M, Oomen L, Verwoerd D, Janssen H, et al. 1996. Direct vesicular transport of MHC class II molecules from lysosomal structures to the cell surface. J. Cell Biol. 135:611-22
105. Kleijmeer M, Ramm G, Schuurhuis D, Griffith J, Rescigno M, et al. 2001. Reorganization of multivesicular bodies regulates MHC class II antigen presentation by dendritic cells. J. Cell Biol. 155:53-63
106. Boes M, Cerny J,MassolR,Op den Brouw M, Kirchhausen T, et al. 2002. T-cell engagement of dendritic cells rapidly rearranges MHC class II transport. Nature 418:983-88
107. Wubbolts R, Fernandez-BorjaM, Jordens I, Reits E, Dusseljee S, et al. 1999. Opposing motor activities of dynein and kinesin determine retention and transport of MHC class II-containing compartments. J. Cell Sci. 112(Pt. 6):785-95
108. Roche PA, Furuta K. 2015. The ins and outs ofMHC class II-mediated antigen processing and presentation. Nat. Rev. Immunol. 15:203-16
109. Rocha N, Neefjes J. 2008. MHC class II molecules on the move for successful antigen presentation. EMBO J. 27:1-5
110. Paul P, van Hoorn T, Jongsma ML, BakkerMJ, Hengeveld R, et al. 2011. A genome-wide multidimensional RNAi screen reveals pathways controllingMHCclass II antigen presentation. Cell 145:268-83
111. Michelet X, Garg S, Wolf BJ, Tuli A, Ricciardi-Castagnoli P, Brenner MB. 2015. MHC class II presentation is controlled by the lysosomal small GTPase, Arl8b. J. Immunol. 194:2079-88
112. KantR, Fish A, JanssenL, JanssenH,Krom S, et al. 2013. Late endosomal transport and tethering are coupled processes controlled by RILP and the cholesterol sensor ORP1L. J. Cell Sci. 126:3462-74
113. Rocha N, Kuijl C, van Kant R, Janssen L, Houben D, et al. 2009. Cholesterol sensor ORP1L contacts the ER protein VAP to control Rab7-RILP-p150Glued and late endosome positioning. J. Cell Biol. 185:1209-25
114. Deretic V, Saitoh T, Akira S. 2013. Autophagy in infection, inflammation and immunity. Nat. Rev. Immunol. 13:722-37
115. Strawbridge AB, Blum JS. 2007. Autophagy in MHC class II antigen processing. Curr. Opin. Immunol. 19:87-92
116. Schmid D, Pypaert M, Munz C. 2007. Antigen-loading compartments for major histocompatibility complex class II molecules continuously receive input from autophagosomes. Immunity 26:79-92
117. Suri A, Walters JJ, Rohrs HW, Gross ML, Unanue ER. 2008. First signature of islet β-cell-derived naturally processed peptides selected by diabetogenic class IIMHC molecules. J. Immunol. 180:3849-56
118. Dongre AR, Kovats S, deRoos P, McCormack AL, Nakagawa T, et al. 2001. In vivo MHC class II presentation of cytosolic proteins revealed by rapid automated tandemmass spectrometry and functional analyses. Eur. J. Immunol. 31:1485-94
119. Dengjel J, Schoor O, Fischer R, Reich M, Kraus M, et al. 2005. Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. PNAS 102:7922-27
120. Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS, Strominger JL. 1993. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J. Exp. Med. 178:27-47
121. Lich JD, Elliott JF, Blum JS. 2000. Cytoplasmic processing is a prerequisite for presentation of an endogenous antigen by major histocompatibility complex class II proteins. J. Exp. Med. 191:1513-24
122. Jaraquemada D, MartiM, Long EO. 1990. An endogenous processing pathway in vaccinia virus-infected cells for presentation of cytoplasmic antigens to class II-restricted T cells. J. Exp. Med. 172:947-54
123. Bonifaz LC, Arzate S, Moreno J. 1999. Endogenous and exogenous forms of the same antigen are processed from different pools to bind MHC class II molecules in endocytic compartments. Eur. J. Immunol. 29:119-31
124. Malnati MS, Marti M, LaVaute T, Jaraquemada D, Biddison W, et al. 1992. Processing pathways for presentation of cytosolic antigen to MHC class II-restricted T cells. Nature 357:702-4
125. Paludan C, Schmid D, Landthaler M, Vockerodt M, Kube D, et al. 2005. Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science 307:593-96
126. Ireland JM, Unanue ER. 2011. Autophagy in antigen-presenting cells results in presentation of citrullinated peptides to CD4 T cells. J. Exp. Med. 208:2625-32
127. Vossenaar ER, van VenrooijWJ. 2004. Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis. Arthritis Res. Ther. 6:107-11
128. Klareskog L, Ronnelid J, Lundberg K, Padyukov L, Alfredsson L. 2008. Immunity to citrullinated proteins in rheumatoid arthritis. Annu. Rev. Immunol. 26:651-75
129. Ireland J,Herzog J,Unanue ER. 2006. Cutting edge:UniqueTcells that recognize citrullinated peptides are a feature of protein immunization. J. Immunol. 177:1421-25
130. Mizushima N, Yamamoto A,MatsuiM, Yoshimori T, Ohsumi Y. 2004. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol. Biol. Cell 15:1101-11
131. Nedjic J, Aichinger M, Emmerich J, Mizushima N, Klein L. 2008. Autophagy in thymic epithelium shapes the T-cell repertoire and is essential for tolerance. Nature 455:396-400
132. AichingerM,Wu C, Nedjic J, Klein L. 2013. Macroautophagy substrates are loaded ontoMHC class II of medullary thymic epithelial cells for central tolerance. J. Exp. Med. 210:287-300
133. Munz C. 2015. Of LAP, CUPS, and DRibbles-unconventional use of autophagy proteins for MHC restricted antigen presentation. Front. Immunol. 6:200
134. Mehta P, Henault J, Kolbeck R, Sanjuan MA. 2014. Noncanonical autophagy: one small step for LC3, one giant leap for immunity. Curr. Opin. Immunol. 26:69-75
135. Sanjuan MA, Dillon CP, Tait SW, Moshiach S, Dorsey F, et al. 2007. Toll-like receptor signalling in macrophages links the autophagy pathway to phagocytosis. Nature 450:1253-57
136. Romao S, Gasser N, Becker AC, Guhl B, BajagicM, et al. 2013. Autophagy proteins stabilize pathogencontaining phagosomes for prolonged MHC II antigen processing. J. Cell Biol. 203:757-66
137. Huang J, Brumell JH. 2014. Bacteria-autophagy interplay: a battle for survival. Nat. Rev. Microbiol. 12:101-14
138. Florey O, Kim SE, Sandoval CP, Haynes CM, Overholtzer M. 2011. Autophagy machinery mediates macroendocytic processing and entotic cell death by targeting single membranes. Nat. Cell Biol. 13:1335-43
139. Ma J, Becker C, Lowell CA, Underhill DM. 2012. Dectin-1-triggered recruitment of light chain 3 protein to phagosomes facilitates major histocompatibility complex class II presentation of fungal-derived antigens. J. Biol. Chem. 287:34149-56
140. Lee HK, Mattei LM, Steinberg BE, Alberts P, Lee YH, et al. 2010. In vivo requirement for Atg5 in antigen presentation by dendritic cells. Immunity 32:227-39
141. ReithW, LeibundGut-Landmann S,Waldburger JM. 2005. Regulation ofMHCclass II gene expression by the class II transactivator. Nat. Rev. Immunol. 5:793-806
142. Wright KL, Ting JP. 2006. Epigenetic regulation of MHC-II and CIITA genes. Trends Immunol. 27:405-12
143. Settembre C, Di Malta C, Polito VA, Garcia Arencibia M, Vetrini F, et al. 2011. TFEB links autophagy to lysosomal biogenesis. Science 332:1429-33
144. Samie M, Cresswell P. 2015. The transcription factor TFEB acts as a molecular switch that regulates exogenous antigen-presentation pathways. Nat. Immunol. 16:729-36
145. Koppelman B, Neefjes JJ, de Vries JE, de Waal Malefyt R. 1997. Interleukin-10 down-regulates MHC class II αβpeptide complexes at the plasma membrane of monocytes by affecting arrival and recycling. Immunity 7:861-71
146. Kuipers HF, Biesta PJ, Groothuis TA, Neefjes JJ, Mommaas AM, van Elsen PJ. 2005. Statins affect cell-surface expression of major histocompatibility complex class II molecules by disrupting cholesterolcontaining microdomains. Hum. Immunol. 66:653-65
147. Watts C, Lanzavecchia A. 1993. Suppressive effect of antibody on processing of T cell epitopes. J. Exp. Med. 178:1459-63
148. Simitsek PD, Campbell DG, Lanzavecchia A, FairweatherN,Watts C. 1995. Modulation of antigen processing by bound antibodies can boost or suppress class IImajor histocompatibility complex presentation of different T cell determinants. J. Exp. Med. 181:1957-63
149. Ziegler HK, Unanue ER. 1982. Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. PNAS 79:175-78
150. Chesnut RW, Colon SM, Grey HM. 1982. Requirements for the processing of antigens by antigenpresenting B cells. I. Functional comparison of B cell tumors andmacrophages. J. Immunol. 129:2382-88
151. Allen PM, Strydom DJ, Unanue ER. 1984. Processing of lysozyme by macrophages: identification of the determinant recognized by two T-cell hybridomas. PNAS 81:2489-93
152. Shimonkevitz R, Colon S, Kappler JW, Marrack P, Grey HM. 1984. Antigen recognition by H-2-restricted T cells. II. A tryptic ovalbumin peptide that substitutes for processed antigen. J. Immunol. 133:2067-74
153. Ziegler K, Unanue ER. 1981. Identification of a macrophage antigen-processing event required for I-region-restricted antigen presentation to T lymphocytes. J. Immunol. 127:1869-75
154. Vergelli M, Pinet V, Vogt AB, Kalbus M, Malnati M, et al. 1997. HLA-DR-restricted presentation of purified myelin basic protein is independent of intracellular processing. Eur. J. Immunol. 27:941-51
155. LindnerR,UnanueER. 1996. Distinct antigenMHCclass II complexes generated by separate processing pathways. EMBO J. 15:6910-20
156. Lee P,Matsueda GR, Allen PM. 1988. T cell recognition of fibrinogen: A determinant on the A α-chain does not require processing. J. Immunol. 140:1063-68
157. Donermeyer DL, Allen PM. 1989. Binding to Ia protects an immunogenic peptide from proteolytic degradation. J. Immunol. 142:1063-68
158. Carrasco-Marin E, Petzold S, Unanue ER. 1999. Two structural states of complexes of peptide and class II major histocompatibility complex revealed by photoaffinity-labeled peptides. J. Biol. Chem. 274:31333-40
159. Cabaniols JP, Cibotti R, Kourilsky P, Kosmatopoulos K, Kanellopoulos JM. 1994. Dose-dependent T cell tolerance to an immunodominant self peptide. Eur. J. Immunol. 24:1743-49
160. Gammon G, Sercarz E. 1989. How some T cells escape tolerance induction. Nature 342:183-85
161. Barlow AK,He X, Janeway C Jr. 1998. Exogenously provided peptides of a self-antigen can be processed into forms that are recognized by self-T cells. J. Exp. Med. 187:1403-15
162. Lovitch SB, Walters JJ, Gross ML, Unanue ER. 2003. APCs present Aβk-derived peptides that are autoantigenic to type B T cells. J. Immunol. 170:4155-60
163. Viner NJ, Nelson CA, Deck B, Unanue ER. 1996. Complexes generated by the binding of free peptides to class II MHC molecules are antigenically diverse compared with those generated by intracellular processing. J. Immunol. 156:2365-68
164. Pu Z, Carrero JA, Unanue ER. 2002. Distinct recognition by two subsets of T cells of an MHC class II-peptide complex. PNAS 99:8844-49
165. Pu Z, Lovitch SB, Bikoff EK, Unanue ER. 2004. T cells distinguish MHC-peptide complexes formed in separate vesicles and edited by H2-DM. Immunity 20:467-76
166. Weigle WO. 1965. The induction of autoimmunity in rabbits following injection of heterologous or altered homologous thyroglobulin. J. Exp. Med. 121:289-308
167. McCluskey RT, Miller F, Benacerraf B. 1962. Sensitization to denatured autologous γglobulin. J. Exp. Med. 115:253-73
168. Rosenthal AS, BarcinskiMA, Blake JT. 1977. Determinant selection is amacrophage dependent immune response gene function. Nature 267:156-58
169. Thomas JW, George-Gattner H, Danho W. 1989. T cells recognize both conformational and cryptic determinants on the insulin molecule. Eur. J. Immunol. 19:557-58
170. Peterson DA, DiPaolo RJ, KanagawaO,Unanue ER. 1999. Quantitative analysis of the T cell repertoire that escapes negative selection. Immunity 11:453-62
171. Wegmann DR, Norbury-Glaser M, Daniel D. 1994. Insulin-specific T cells are a predominant component of islet infiltrates in pre-diabetic NOD mice. Eur. J. Immunol. 24:1853-57
172. Daniel D, Gill RG, Schloot N, Wegmann D. 1995. Epitope specificity, cytokine production profile and diabetogenic activity of insulin-specific T cell clones isolated from NOD mice. Eur. J. Immunol. 25:1056-62
173. Mohan JF, Levisetti MG, Calderon B, Herzog JW, Petzold SJ, Unanue ER. 2010. Unique autoreactive T cells recognize insulin peptides generated within the islets of Langerhans in autoimmune diabetes. Nat. Immunol. 11:350-54
174. Mohan JF, Petzold SJ, Unanue ER. 2011. Register shifting of an insulin peptide-MHC complex allows diabetogenic T cells to escape thymic deletion. J. Exp. Med. 208:2375-83
175. Unanue ER. 2014. Antigen presentation in the autoimmune diabetes of the NOD mouse. Annu. Rev. Immunol. 32:579-608
176. Anderton SM. 2004. Post-translational modifications of self antigens: implications for autoimmunity. Curr. Opin. Immunol. 16:753-58
177. Petersen J, Purcell AW, Rossjohn J. 2009. Post-translationally modified T cell epitopes: immune recognition and immunotherapy. J. Mol. Med. 87:1045-51
178. Birnboim HC, Lemay AM, Lam DK, Goldstein R, Webb JR. 2003. Cutting edge MHC class II-restricted peptides containing the inflammation-associated marker 3-nitrotyrosine evade central tolerance and elicit a robust cell-mediated immune response. J. Immunol. 171:528-32
179. Herzog J, Maekawa Y, Cirrito TP, Illian BS,Unanue ER. 2005. Activated antigen-presenting cells select and present chemically modified peptides recognized by unique CD4 T cells. PNAS 102:7928-33
180. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E. 2003. Cutting edge the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1∗0401 MHC class II molecule. J. Immunol. 171:538-41
181. Koning F, Thomas R, Rossjohn J, Toes RE. 2015. Coeliac disease and rheumatoid arthritis: similar mechanisms, different antigens. Nat. Rev. Rheumatol. 11:450-61
182. Gregersen PK, Goyert SM, Song QL, Silver J. 1987. Microheterogeneity of HLA-DR4 haplotypes: DNA sequence analysis of LD"KT2" and LD"TAS" haplotypes. Hum. Immunol. 19:287-92
183. Scally SW, Petersen J, Law SC, Dudek NL, Nel HJ, et al. 2013. A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. J. Exp. Med. 210:2569-82
184. Cordova KN, Willis VC, Haskins K, Holers VM. 2013. A citrullinated fibrinogen-specific T cell line enhances autoimmune arthritis in a mouse model of rheumatoid arthritis. J. Immunol. 190:1457-65
185. James EA, Rieck M, Pieper J, Gebe JA, Yue BB, et al. 2014. Citrulline-specific Th1 cells are increased in rheumatoid arthritis and their frequency is influenced by disease duration and therapy. Arthritis Rheumatol. 66:1712-22
186. Backlund J, Carlsen S, Hoger T,Holm B, Fugger L, et al. 2002. Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritis. PNAS 99:9960-65
187. Cao L, SunD,Whitaker JN. 1998. Citrullinated myelin basic protein induces experimental autoimmune encephalomyelitis in Lewis rats through a diverse T cell repertoire. J. Neuroimmunol. 88:21-29
188. Moscarello MA, Mastronardi FG,Wood DD. 2007. The role of citrullinated proteins suggests a novel mechanism in the pathogenesis of multiple sclerosis. Neurochem. Res. 32:251-56
189. Rose NR. 2011. The genetics of autoimmune thyroiditis: the first decade. J. Autoimmun. 37:88-94
190. Braley-Mullen H, Yu S. 2015. NOD.H-2h4 mice: an important and underutilized animal model of autoimmune thyroiditis and Sjogren's syndrome. Adv. Immunol. 126:1-43
191. Kolypetri P, Carayanniotis K, Rahman S, Georghiou PE, Magafa V, et al. 2014. The thyroxinecontaining thyroglobulin peptide (aa 2549-2560) is a target epitope in iodide-accelerated spontaneous autoimmune thyroiditis. J. Immunol. 193:96-101
192. Sollid LM, Jabri B. 2011. Celiac disease and transglutaminase 2: a model for posttranslational modification of antigens andHLA association in the pathogenesis of autoimmune disorders. Curr. Opin. Immunol. 23:732-38
193. Fallang LE, Bergseng E, Hotta K, Berg-Larsen A, Kim CY, Sollid LM. 2009. Differences in the risk of celiac disease associated with HLA-DQ2.5 or HLA-DQ2.2 are related to sustained gluten antigen presentation. Nat. Immunol. 10:1096-101
194. Hovhannisyan Z, Weiss A, Martin A,Wiesner M, Tollefsen S, et al. 2008. The role of HLA-DQ8 β57 polymorphism in the anti-gluten T-cell response in coeliac disease. Nature 456:534-38
195. Molberg O, McAdam SN, Korner R, Quarsten H, Kristiansen C, et al. 1998. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat. Med. 4:713-17
196. Qiao SW, Bergseng E, Molberg O, Jung G, Fleckenstein B, Sollid LM. 2005. Refining the rules of gliadin T cell epitope binding to the disease-associated DQ2 molecule in celiac disease: importance of proline spacing and glutamine deamidation. J. Immunol. 175:254-61
197. Tye-Din JA, Stewart JA, Dromey JA, Beissbarth T, Heel DA, et al. 2010. Comprehensive, quantitative mapping of T cell epitopes in gluten in celiac disease. Sci. Transl. Med. 2:41ra51
198. Petersen J, Montserrat V, Mujico JR, Loh KL, Beringer DX, et al. 2014. T-cell receptor recognition of HLA-DQ2-gliadin complexes associated with celiac disease. Nat. Struct. Mol. Biol. 21:480-88
199. Jones VE, Leskowitz S. 1965. Role of the carrier in development of delayed sensitivity to the azophenylarsonate group. Nature 207:596-97
200. Thomas DW. 1978. Hapten-specific T lymphocyte activation by glutaraldehyde-treated macrophages: an argument against antigen processing by macrophages. J. Immunol. 121:1760-66
201. Falta MT, Pinilla C, Mack DG, Tinega AN, Crawford F, et al. 2013. Identification of berylliumdependent peptides recognized by CD4+ T cells in chronic beryllium disease. J. Exp. Med. 210:1403-18
202. Fontenot AP, Keizer TS, McCleskey M, Mack DG, Meza-Romero R, et al. 2006. Recombinant HLADP2 binds beryllium and tolerizes beryllium-specific pathogenicCD4+ Tcells. J. Immunol. 177:3874-83
203. Bill JR, Mack DG, Falta MT, Maier LA, Sullivan AK, et al. 2005. Beryllium presentation to CD4+ T cells is dependent on a single amino acid residue of theMHC class II β-chain. J. Immunol. 175:7029-37
204. Clayton GM, Wang Y, Crawford F, Novikov A, Wimberly BT, et al. 2014. Structural basis of chronic beryllium disease: linking allergic hypersensitivity and autoimmunity. Cell 158:132-42
205. Wang Y, Dai S. 2013. Structural basis of metal hypersensitivity. Immunol. Res. 55:83-90
206. Kalish RS, Johnson KL. 1990. Enrichment and function of urushiol (poison ivy)-specific T lymphocytes in lesions of allergic contact dermatitis to urushiol. J. Immunol. 145:3706-13
207. Illing PT, Vivian JP, Dudek NL, Kostenko L, Chen Z, et al. 2012. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 486:554-58